ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
BERKELEY, Calif., May 15, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the Company’s new strategic initiatives and value drivers at the UBS Global Healthcare Conference on Monday, May 22, 2017, at 8:30 a.m. ET. The conference is being held at the Grand Hyatt New York hotel.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
